# Role of the TGF-beta pathway in stem cell aging

## Molecular Architecture of the Transforming Growth Factor-Beta Superfamily

The transforming growth factor-beta (TGF-β) superfamily constitutes a highly conserved and functionally pleiotropic group of secreted polypeptide signaling molecules that regulate a vast array of biological processes. These processes range from gastrulation, embryonic body plan patterning, and mesoderm induction during early development to the maintenance of tissue homeostasis, immune regulation, and wound healing in adult organisms [cite: 1, 2, 3]. Comprising over 30 distinct members in mammals, the superfamily is systematically subdivided into several major subclasses based on structural and functional similarities. These include the TGF-β isoforms (TGF-β1, TGF-β2, TGF-β3, and TGF-β4), bone morphogenetic proteins (BMPs), growth differentiation factors (GDFs), activins, inhibins, Nodal, Lefty, Mullerian Inhibiting Substance (MIS), and glial-derived neurotrophic factors (GDNFs) [cite: 2, 3, 4]. Proteins within this family share approximately 25-40% amino acid sequence identity and are characterized by a highly conserved structural motif known as the cysteine knot [cite: 2].

The fundamental mechanism of signal transduction for the majority of these ligands relies on their interaction with transmembrane serine/threonine kinase receptors. The active signaling complex is a heterotetramer composed of two type II and two type I receptor subunits. Both receptor types possess extracellular ligand-binding domains and intracellular serine/threonine kinase domains [cite: 2, 5, 6]. The mammalian genome encodes five distinct type II receptors and seven type I receptors, the latter frequently designated as activin receptor-like kinases (ALKs) [cite: 5, 6]. The specificity of the signaling cascade is dictated by the precise combination of these receptor subunits. The type I receptor is distinguished by a highly conserved approximately 30-residue intracellular juxtamembrane region termed the GS domain, which contains a characteristic SGSGSG amino acid sequence essential for its activation [cite: 2]. 

In a departure from the standard serine/threonine kinase paradigm, the GDNF subfamily ligands utilize a distinct receptor mechanism. GDNF, neurturin, persephin, and artemin initially bind to a specific glycosylphosphatidylinositol-anchored coreceptor, GFRalpha (particularly GFRalpha1 for GDNF). This initial binding facilitates the subsequent association with two subunits of the Ret receptor tyrosine kinase. The formation of this 2:2:2 ligand-GFRalpha-Ret complex induces Ret autophosphorylation, creating intracellular docking sites for adaptor proteins that initiate downstream cascades, including the Ras/MAPK, PI3K/Akt, and PLC-gamma/PKC pathways [cite: 2, 3].

### Canonical and Non-Canonical Signal Transduction

Upon ligand binding to the heterotetrameric complex of serine/threonine kinase receptors, the constitutively active type II receptor phosphorylates the GS domain of the type I receptor, thereby activating its kinase function. The activated type I receptor subsequently phosphorylates specific cytoplasmic substrates known as receptor-regulated SMADs (R-SMADs) [cite: 5, 7, 8]. The choice of R-SMAD dictates the primary branch of the canonical signaling pathway. The TGF-β and activin/myostatin subclasses, which primarily signal through ALK4, ALK5, and ALK7, induce the phosphorylation of SMAD2 and SMAD3 [cite: 5, 6, 9]. Conversely, the BMP and certain GDF subclasses, signaling via ALK1, ALK2, ALK3, and ALK6, typically induce the phosphorylation of SMAD1, SMAD5, and SMAD8 [cite: 8, 9].

Once phosphorylated, these R-SMADs dissociate from the receptor complex and oligomerize with the common-mediator SMAD4 (co-SMAD) [cite: 7, 9]. This heteromeric SMAD complex then translocates into the nucleus, where it functions as a critical transcriptional regulator. Because SMADs exhibit relatively low intrinsic DNA-binding affinity, they must associate with a myriad of DNA-binding cofactors, coactivators (such as CBP/p300), and corepressors to regulate the transcription of target genes in a highly context-dependent and cell-type-specific manner [cite: 8, 10, 11].

Simultaneously, the engagement of TGF-β superfamily receptors triggers multiple non-canonical, SMAD-independent signaling pathways. These parallel cascades include the phosphoinositide 3-kinase (PI3K)/Akt pathway, the mechanistic target of rapamycin (mTOR) network, and various mitogen-activated protein kinase (MAPK) pathways, including extracellular signal-regulated kinases (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 MAPK [cite: 2, 9, 12]. The biological outcome of TGF-β signaling—whether it drives proliferation, induces apoptosis, maintains stem cell quiescence, or promotes extracellular matrix deposition—is determined by the intricate, dynamic integration of these canonical and non-canonical pathways within a specific cellular microenvironment.

### Age-Dependent Receptor Stoichiometry and Signal Diversion

The aging process fundamentally alters the landscape of TGF-β signaling not only through changes in ligand availability but also via critical shifts in receptor stoichiometry. The progressive degeneration of articular cartilage in osteoarthritis (OA), a primary age-related pathology, exemplifies this phenomenon. In healthy, youthful cartilage, TGF-β1 is chondroprotective and crucial for maintaining chondrocyte homeostasis, stimulating the synthesis of type II collagen and proteoglycans while suppressing catabolic enzymes such as matrix metalloproteinase-13 (MMP-13) [cite: 10, 13]. This protective function is mediated predominantly through the ALK5 receptor, which phosphorylates SMAD2/3 [cite: 10, 13].

However, chondrocytes also express ALK1, which phosphorylates SMAD1/5/8. ALK1 typically forms a heterodimer with ALK5, making its signaling dependent on ALK5 presence [cite: 13]. With advancing age, the absolute levels of ALK5 decrease significantly, altering the functional ratio of ALK1 to ALK5 on the cell surface [cite: 10, 13]. Consequently, the identical TGF-β1 ligand, which previously initiated an anabolic, protective cascade via SMAD2/3, is increasingly diverted through the ALK1/SMAD1/5/8 axis. This age-associated shift fundamentally re-wires the cellular response, transforming TGF-β1 into a catabolic factor that drives chondrocyte hypertrophy, terminal differentiation, and the expression of collagenase MMP-13, directly precipitating cartilage degradation and osteoarthritis progression [cite: 10, 13]. 

| TGF-β Superfamily Subclass | Primary Ligands | Primary Type I Receptors | Canonical R-SMADs | Principal Biological Functions |
| :--- | :--- | :--- | :--- | :--- |
| **TGF-β Isoforms** | TGF-β1, TGF-β2, TGF-β3 | ALK5 | SMAD2, SMAD3 | Immune regulation, cellular senescence, global fibrogenesis, stem cell quiescence. |
| **Activins & Myostatins** | Activin A, GDF8, GDF11 | ALK4, ALK5, ALK7 | SMAD2, SMAD3 | Menstrual regulation, negative regulation of muscle mass (GDF8), developmental patterning (GDF11). |
| **BMPs & other GDFs** | BMP2, BMP4, GDF1, GDF3 | ALK1, ALK2, ALK3, ALK6 | SMAD1, SMAD5, SMAD8 | Bone and cartilage induction, dorso-ventral patterning, mesoderm induction. |
| **GDNFs** | GDNF, Neurturin, Persephin | GFRalpha (coreceptor) + Ret | Non-SMAD (Ras, PI3K) | Neuronal survival, differentiation, peripheral nervous system development. |

## Stem Cell Quiescence and Activation Dynamics

Adult somatic stem cells are essential for lifelong tissue homeostasis and the regeneration of organs following injury. To preserve this regenerative potential and prevent premature exhaustion or malignant transformation, stem cells are maintained in a state of quiescence— a reversible, stable withdrawal from the cell cycle (G0 phase) characterized by low metabolic activity, reduced transcription and translation, and a heavy reliance on fatty acid oxidation [cite: 14, 15, 16]. 

### The Double-Edged Sword of Quiescence

While quiescence protects stem cells from the accumulation of replication-induced DNA damage and oxidative stress over an organism's lifespan, this protective state exacts a physiological toll. Quiescent cells exhibit a reduced expression of critical DNA repair factors. When DNA damage does occur, quiescent stem cells frequently utilize error-prone non-homologous end joining (NHEJ) mechanisms rather than high-fidelity homologous recombination, which requires an active cell cycle [cite: 14, 17]. 

Furthermore, the activation of a quiescent stem cell—the process of re-entering the cell cycle to undergo asymmetric or symmetric division—is a highly orchestrated, metabolically demanding event. It requires precise epigenetic modulations, a massive upregulation in protein synthesis, mitochondrial biogenesis, and a fundamental shift in metabolic pathways [cite: 14]. As organisms age, the regulatory circuits controlling quiescence maintenance and exit progressively fail. Stem cells may experience aberrant, stochastic activation leading to clonal exhaustion, or conversely, they may be driven into a state of "deep quiescence" from which they cannot effectively emerge in response to tissue damage [cite: 15, 16].

### Transforming Growth Factor-Beta as an Enforcer of Quiescence

The TGF-β signaling pathway serves as a primary, systemic enforcer of the quiescent state across diverse somatic stem cell compartments, including hematopoietic stem cells (HSCs), neural stem cells (NSCs), and muscle stem cells (MuSCs) [cite: 14, 15, 18]. TGF-β exerts its potent cytostatic effects primarily through the transcriptional induction of cyclin-dependent kinase inhibitors, particularly p15 (Ink4b), p16 (Ink4a), p21 (Cip1), and p27 (Kip1) [cite: 12, 14, 18]. Simultaneously, SMAD complexes directly repress the transcription of major proliferation drivers, most notably the proto-oncogene c-Myc [cite: 12, 18]. 

In youthful tissues, this inhibitory network correctly balances self-renewal and differentiation, preventing stem cell exhaustion. However, the age-related systemic elevation of TGF-β ligands fundamentally distorts this balance. In the aged hippocampus, for example, the local accumulation of TGF-β1 acts on neural progenitor cells (NPCs) to enforce permanent cell cycle exit and suppress neurogenesis, contributing to cognitive decline [cite: 19, 20, 21]. By experimentally dampening TGF-β1/pSMAD signaling using pharmacological inhibitors, researchers have demonstrated that it is possible to rescue neural stem cells from deep quiescence and functionally rejuvenate neurogenesis to youthful levels [cite: 19, 21]. Similar dynamics occur in the hematopoietic system, where aged HSCs exhibit an increased propensity for deep quiescence, delayed cell cycle entry, and a concomitant reduction in Akt signaling responsiveness, driven largely by inflammatory alterations in the bone marrow microenvironment [cite: 15, 16, 17].

## Age-Related Deterioration of the Stem Cell Niche

Stem cells do not operate in isolation; their behavior is heavily dictated by their local microenvironment, or niche. The stem cell niche is a complex, dynamic structural network comprising diverse supporting cell types (such as endothelial cells, fibroblasts, pericytes, and immune cells), the extracellular matrix (ECM), and a precise gradient of soluble and tethered signaling factors [cite: 15, 16, 22]. The spatial and morphological deterioration of the cellular niche is characterized by the physical accumulation of matrix fibers and paracrine loops that trap the stem cell in deep quiescence. Aging disrupts not only the intrinsic properties of the stem cells but also the physical and biochemical integrity of the niche, creating an environment that actively suppresses regeneration [cite: 15, 16].

### Vascular and Immune Contributions to Niche Aging

The vascular endothelium serves as a critical component of many stem cell niches, delivering oxygen, nutrients, and angiocrine signals. In the adult mouse brain, the hippocampal neurogenic niche undergoes severe vascular deterioration with age. Endothelial cells in the aged niche upregulate the expression and secretion of TGF-β1, which bathes adjacent neural stem cells [cite: 20]. This vascular-derived TGF-β acts as an extrinsic brake, severely perturbing neurogenesis [cite: 20]. Similarly, exposure to radiation, which mimics aspects of accelerated tissue aging, induces a massive surge in local TGF-β production within the neurogenic niche, leading to a profound collapse of the stem cell pool [cite: 20].

Immune cells, particularly macrophages and microglia, also undergo age-related phenotypic shifts that poison the niche. In the aged hippocampus, resident microglia elevate their production of TGF-β1, which drives a localized pro-inflammatory state [cite: 19]. This is characterized by the elevated expression of beta-2 microglobulin (B2M), an MHC class I molecule associated with cognitive impairment and systemic aging [cite: 19]. Intriguingly, while TGF-β1 is canonically considered an anti-inflammatory cytokine, at the high concentrations typically found in aged tissues, its function appears to invert, promoting chronic, low-grade inflammation that suppresses stem cell output [cite: 19].

### Evolutionary Conservation in Invertebrate Models

The fundamental principles governing the communication between stem cells and their niches are deeply conserved across evolution. The free-living nematode *Caenorhabditis elegans* serves as a premier model for delineating these interactions due to its transparent body, genetic tractability, short lifespan, and fully mapped cellular lineage [cite: 1, 22]. In *C. elegans*, the TGF-β superfamily is represented by specific ligand-receptor pathways, most notably the DAF-7 (ligand) and SMA-3 (SMAD) cascades. 

Genetic studies in *C. elegans* first established the critical role of the insulin/IGF-1 signaling (IIS) pathway (via the daf-2 receptor) in regulating organismal longevity and stem cell function [cite: 1, 22]. Recent research has demonstrated that the DAF-7 TGF-β signaling pathway intricately integrates with the IIS pathway, AMPK, and mTOR networks to govern the maintenance of germline stem cells [cite: 1]. As the somatic niche cells of the nematode age, their physical and chemical interactions with the germline stem cells deteriorate, driven by alterations in these highly conserved pathways. Modulating TGF-β signaling within the *C. elegans* niche can preserve germline stem cell function and extend reproductive lifespan, providing foundational insights into how niche-targeted interventions might rejuvenate mammalian stem cells [cite: 1, 22, 23].

## Crosstalk Between Transforming Growth Factor-Beta and Developmental Pathways

The biological outcomes of TGF-β signaling are heavily modulated by its extensive crosstalk with other major developmental and homeostatic pathways, including Notch, Wnt, and mTOR. These interactions occur dynamically at the transcriptional level and via direct protein-protein interactions, serving as critical integrators of cellular stress, nutrient availability, and fate determination [cite: 8, 24, 25].

### Integration with Notch Signaling

The Notch signaling pathway dictates cell fate through direct cell-cell contact. Upon ligand binding (e.g., Delta or Jagged), the Notch receptor undergoes proteolytic cleavage, releasing the Notch Intracellular Domain (NICD), which translocates to the nucleus to complex with the CSL (RBP-Jk/CBF1) DNA-binding protein and initiate the transcription of target genes such as Hes and Hey families [cite: 8, 11]. 

The convergence of the Notch and TGF-β pathways is critical in aged stem cell dynamics and tissue fibrogenesis. Biochemical analyses demonstrate a direct, ligand-dependent protein-protein interaction between NICD and Smad3, both *in vitro* and within the cellular nucleus [cite: 11]. The presence of NICD and CSL facilitates the recruitment of Smad3 to CSL-binding sites on the genome, creating a synergistic transcriptional complex [cite: 11]. In cultured human Müller stem cells and adult neural stem cells, the application of exogenous TGF-β1 directly downregulates specific Wnt ligands (e.g., Wnt2b) while simultaneously inducing the expression of the Notch target gene Hes-1 [cite: 11, 24]. This molecular cross-wiring ensures that the aged stem cell is locked into a quiescent, undifferentiated state, incapable of initiating the necessary Wnt-driven proliferative expansion required for neurogenesis or tissue repair.

In the context of fibrosis, TGF-β1 and Notch exhibit a reciprocal, feed-forward activation loop. In alveolar epithelial cells and fibroblasts, TGF-β1 treatment dramatically upregulates the expression of Notch receptors (Notch2, Notch3, Notch4) and the Jagged1 ligand [cite: 25]. The resulting overactivation of Notch signaling drives epithelial-mesenchymal transition (EMT) and the differentiation of resting fibroblasts into hyperactive, alpha-smooth muscle actin (α-SMA)-expressing myofibroblasts. Conversely, the specific pharmacological inhibition of Notch signaling (e.g., via γ-secretase inhibitors like DAPT) significantly attenuates TGF-β1-induced EMT and collagen synthesis, underscoring the dependency of TGF-β fibrotic programs on active Notch signaling [cite: 24, 25].

### Crosstalk with mTOR and Epigenetic Regulators (AMPK/SIRT1)

The mechanistic target of rapamycin (mTOR) is the master regulator of nutrient sensing, protein synthesis, and cellular growth [cite: 1, 26]. Chronic activation of the mTOR pathway, particularly mTORC1, is a primary driver of organismal aging and chronic inflammation [cite: 9, 26]. The interaction between mTOR and TGF-β is profound in the context of tissue homeostasis. While physiological mTOR signaling promotes tissue regeneration, its hyperactivation impairs macroautophagy, a process essential for clearing damaged organelles and proteins [cite: 27]. The failure of autophagy in aged cells directly upregulates TGF-β signaling, creating a pro-fibrotic environment. Consequently, mTOR inhibitors such as rapamycin mitigate aspects of age-related fibrosis, though their suppressive effect on general wound healing highlights the complexity of the network [cite: 26].

Furthermore, cellular energy sensors such as AMP-activated protein kinase (AMPK) and the NAD+-dependent deacetylase Sirtuin 1 (SIRT1) directly intercept the TGF-β pathway. Activation of AMPK, via caloric restriction or compounds like metformin, inhibits TGF-β-induced collagen production [cite: 27]. SIRT1 exerts an anti-fibrotic effect by physically deacetylating Smad4, thereby crippling the ability of the Smad2/3/4 complex to initiate the transcription of pro-fibrotic and pro-senescence genes [cite: 27]. As SIRT1 levels naturally decline with age, the repressor on Smad4 is lifted, permitting rampant TGF-β transcriptional activity and accelerating the fibrotic deterioration of aging tissues.

| Intersecting Pathway | Key Molecular Mediators | Mechanism of Crosstalk with TGF-β | Functional Consequence in Aging |
| :--- | :--- | :--- | :--- |
| **Notch** | NICD, CSL, Hes-1 | Direct physical binding of Smad3 to NICD/CSL at target promoters. | Enforces deep stem cell quiescence; accelerates myofibroblast differentiation. |
| **Wnt/β-catenin** | β-catenin, Wnt2b | TGF-β suppresses Wnt ligands but can synergize with β-catenin in senescent cells. | Prevents stem cell proliferation; promotes senescence-associated EMT. |
| **mTOR** | mTORC1, Rapamycin | mTOR hyperactivation impairs autophagy, causing upstream accumulation of TGF-β. | Promotes systemic chronic inflammation and age-associated tissue fibrosis. |
| **SIRT1 / AMPK** | SIRT1, Smad4, NAD+ | SIRT1 deacetylates Smad4, acting as a brake on TGF-β target gene transcription. | Age-related SIRT1 decline unleashes TGF-β activity, driving massive ECM deposition. |

## Cellular Senescence and Organ-Specific Fibrogenesis

The ultimate physiological manifestations of aging—loss of organ compliance, mechanical stiffness, and structural failure—are predominantly driven by the parallel accumulation of senescent cells and extracellular matrix proteins, processes fundamentally orchestrated by TGF-β.

### The Senescence-Associated Secretory Phenotype (SASP)

Cellular senescence is a permanent state of cell cycle arrest triggered by severe DNA damage, telomere attrition, oxidative stress, or oncogene activation [cite: 12, 18, 27]. Senescent cells do not undergo apoptosis; rather, they accumulate in aging tissues and adopt a hyper-secretory profile known as the senescence-associated secretory phenotype (SASP) [cite: 12, 27, 28]. The SASP is a potent cocktail of pro-inflammatory cytokines (IL-6, IL-8), matrix remodeling enzymes, and growth factors, with TGF-β serving as one of its most critical components [cite: 12].

The secretion of TGF-β by senescent cells creates a destructive paracrine loop. First, it exerts a "bystander effect," acting on adjacent, healthy epithelial and endothelial cells to force them into premature senescence [cite: 12, 27]. Second, the secreted TGF-β heavily recruits and hyperactivates resident tissue fibroblasts. These fibroblasts transdifferentiate into myofibroblasts, characterized by massive synthesis of type I collagen and fibronectin, while simultaneously downregulating matrix degradation enzymes [cite: 9, 12, 25]. 

This interplay involves profound epigenetic reprogramming. Prolonged TGF-β signaling in aged fibroblasts downregulates the expression of the histone methyltransferase Suv4-20h via the upregulation of microRNAs miR-29a and miR-29c [cite: 18, 27]. This results in the loss of trimethylation at histone H4 lysine 20 (H4K20me3), a critical epigenetic mark required for heterochromatin maintenance and DNA damage repair. The loss of H4K20me3 directly accelerates cellular senescence and systemic aging [cite: 18]. Furthermore, TGF-β accelerates telomere attrition by downregulating the transcription of the catalytic subunit of telomerase (hTERT), an effect achieved indirectly through the Smad-mediated suppression of the c-Myc oncogene [cite: 12].

Further illuminating the link between TGF-β and senescence is the rare premature aging disorder gerodermia osteodysplastica (GO), caused by loss-of-function mutations in the GORAB gene, a key regulator of Golgi vesicle transport [cite: 29]. GORAB deficiency results in disorganized extracellular matrices that physically cause a massive overactivation of the TGF-β signaling pathway. In affected fibroblasts and osteoblast lineages, this excessive TGF-β signaling drastically upregulates the expression of Nox4, leading to the lethal overproduction of mitochondrial superoxide. The resulting oxidative stress causes widespread DNA damage and severe cellular senescence, culminating in early-onset osteoporosis, a phenotype that can be experimentally rescued using the TGF-β neutralizing antibody 1D11 [cite: 29].

### Mechanisms of Organ Fibrosis

While the TGF-β/Smad axis is universally utilized, its specific execution drives distinct pathologies across various organs:

*   **Idiopathic Pulmonary Fibrosis (IPF):** IPF is an age-associated, frequently fatal disease characterized by progressive lung scarring. The aging pulmonary epithelium loses its regenerative capacity following recurrent micro-injuries. Elevated TGF-β1, often operating through the MEK/ERK and IL-11 cascades, induces premature senescence in alveolar cells and forces a massive epithelial-to-mesenchymal transition, replacing delicate gas-exchange tissue with rigid fibrotic scarring [cite: 18, 27].
*   **Cardiac Fibrosis:** In the aging heart, the deposition of fibrotic tissue between cardiomyocytes leads to increased ventricular stiffness and heart failure with preserved ejection fraction. The TGF-β pathway is the primary activator of cardiac fibroblasts. Specifically, the age-associated upregulation of miRNA-1468-3p in human cardiac fibroblasts increases senescence markers (SA-β-gal, p16, p53) while simultaneously hyperactivating the TGF-β1-p38 signaling axis, resulting in massive collagen I deposition and pathological cardiac remodeling [cite: 12, 18].
*   **Liver and Kidney Fibrosis:** In hepatic tissue, TGF-β is the central driver forcing quiescent hepatic stellate cells (HSCs) to transdifferentiate into active myofibroblasts, leading to cirrhosis [cite: 9, 25, 27]. In the kidney, TGF-β mediates tubular injury, massive ECM deposition, and the progression of diabetic nephropathy and chronic kidney disease [cite: 9, 12, 27].

## The Growth Differentiation Factor 11 Paradigm and Controversy

No single member of the TGF-β superfamily has generated more intense scientific scrutiny, optimism, and subsequent controversy in the field of aging biology than Growth Differentiation Factor 11 (GDF11), alongside its close homolog Growth Differentiation Factor 8 (GDF8), widely known as Myostatin. 

### Structural Homology and Divergence

GDF11 and Myostatin share an extraordinary 89% amino acid sequence identity within their mature, biologically active C-terminal signaling domains [cite: 4, 6, 30]. Both ligands assemble symmetrical, propeller-like homodimers that interact with nearly identical cell-surface receptors. They both utilize the type II receptors ActRIIA and ActRIIB, and signal through the type I receptors ALK4, ALK5, and ALK7 to phosphorylate and activate SMAD2 and SMAD3 [cite: 5, 6, 31]. Given this profound sequence and receptor overlap, early hypotheses posited that the two ligands performed largely redundant functions [cite: 30, 31].

However, significant biochemical and functional divergences separate them. A primary difference lies in their N-terminal prodomains, which share only 52% sequence identity [cite: 4, 5, 6]. Similar to other TGF-β proteins, GDF11 and GDF8 are synthesized as latent precursors. Following initial cleavage by furin proteases, the mature C-terminal domains of both GDF11 and GDF8 remain tightly, non-covalently bound to their prodomains, preventing receptor interaction [cite: 4, 6]. Activation uniquely requires a secondary proteolytic cleavage by Tolloid (TLD) family metalloproteinases. While GDF8 is preferentially cleaved by TLL2, GDF11 relies on BMP1 and TLL1 [cite: 6, 32]. 

Crucially, rigorous structural and *in vitro* comparative studies have demonstrated that despite binding the same receptors, GDF11 is a vastly more potent signaling molecule than Myostatin. GDF11 induces SMAD2/3 phosphorylation at significantly lower ligand concentrations across various primary cell lines and in the myocardium *in vivo* [cite: 6, 30, 31]. Domain-swapping genetic experiments in mice, which substituted unique amino acids from the GDF11 fingertip region into the GDF8 locus, confirmed that the structural nuances of GDF11 facilitate a more efficient, high-affinity interaction with the type I ALK receptors [cite: 30, 31].

### The Systemic "Youth Factor" Hypothesis vs. The Pro-Aging Paradigm

The biological function of GDF11 in adulthood became the center of a major scientific debate beginning in 2013. Initial high-profile reports utilized heterochronic parabiosis—the surgical anastomosis of the circulatory systems of young and aged mice—to investigate systemic aging factors [cite: 6]. These early studies concluded that GDF11 is a circulating "youth factor." They reported that circulating GDF11 levels decline significantly with advancing age, and that the exogenous systemic administration of recombinant GDF11 to aged mice could dramatically reverse cardiac hypertrophy, enhance skeletal muscle regeneration and strength, and rescue age-related cognitive dysfunction and olfactory neurogenesis [cite: 5, 6, 33, 34].

This narrative of GDF11 as a pan-organ anti-aging therapeutic was swiftly challenged by subsequent independent investigations, sparking a profound controversy in the field [cite: 6, 35]. Researchers from Novartis and other independent institutions argued that the assays used in the initial studies (specifically SOMAmer technology and non-specific western blotting antibodies) failed to accurately distinguish between GDF11 and the highly homologous GDF8 (Myostatin) [cite: 5, 6, 34]. 

Upon deploying highly specific immunoassays and tandem mass spectrometry capable of differentiating the two ligands, multiple groups reported fundamentally contradictory results:
1.  **Circulating Levels:** High-specificity assays indicated that circulating GDF11 levels do not decline with age; rather, they remain stable or actually *increase* in the sera of older individuals and rodents [cite: 5, 33, 34, 36]. Elevated GDF11 was found to positively correlate with frailty, osteoporosis, and sarcopenia [cite: 33, 37].
2.  **Muscle and Cardiac Function:** Subsequent physiological studies found that, far from being regenerative, exogenous GDF11 acts similarly to Myostatin in skeletal muscle. Supraphysiological doses of GDF11 block myoblast differentiation, inhibit satellite cell expansion, and induce severe skeletal muscle atrophy by upregulating the ubiquitin-proteasome pathway markers Atrogin-1 and MuRF1 via SMAD3 phosphorylation [cite: 5, 33, 34, 37]. Furthermore, several groups failed to replicate the rescue of age-related cardiac hypertrophy, reporting instead that systemic GDF11 induced cachexia and exacerbated mortality [cite: 6, 34, 37].

### Resolution and Current Consensus

The ongoing consensus resolving this controversy points toward profound dose-dependency, tissue-specific expression, and genetic background variability [cite: 5, 6, 35]. GDF11 is unequivocally essential for embryonic development; complete knockouts (Gdf11 -/-) suffer perinatal lethality due to severe anterior/posterior skeletal transformations, cleft palate, and renal agenesis [cite: 4, 37]. However, in adulthood, GDF11 operates as a highly potent, locally acting paracrine regulator. 

While its role in specific micro-environments (such as preserving endothelial function or regulating certain neuronal populations) may be beneficial, raising systemic circulating levels of GDF11 to supraphysiological concentrations invariably triggers the catabolic, pro-fibrotic, and anti-regenerative cascades characteristic of the broader TGF-β/SMAD signaling network [cite: 5, 6, 35]. 

| Biological Parameter | Growth Differentiation Factor 11 (GDF11) | Growth Differentiation Factor 8 (Myostatin) |
| :--- | :--- | :--- |
| **Developmental Requirement** | Essential. Knockouts are perinatally lethal (skeletal/renal defects). | Dispensable for survival. Knockouts yield hypermuscular phenotypes. |
| **Expression Pattern** | Widespread in adult tissues (brain, spleen, heart, kidney, muscle). | Highly restricted exclusively to skeletal muscle. |
| **Tolloid Cleavage Specificity** | Cleaved primarily by BMP1 and TLL1. | Cleaved primarily by TLL2. |
| **Receptor Binding Potency** | Exceptionally high potency/affinity for ALK4/5/7. | Lower relative potency for ALK4/5. |
| **Effect on Skeletal Muscle** | Debated; high systemic doses induce severe atrophy via Atrogin-1/MuRF1. | Established negative regulator; suppresses fiber hypertrophy. |

## Pharmacological Interventions and Cellular Rejuvenation

The recognition that the TGF-β pathway acts as a fundamental, systemic brake on stem cell function and driver of fibrosis has catalyzed an extensive search for targeted pharmacological inhibitors. Re-calibrating this pathway from an aged, hyperactivated state back to youthful baseline levels represents one of the most promising frontiers in anti-aging medicine and regenerative biology.

### Small Molecule Cocktails and Partial Cellular Reprogramming

The discovery that adult somatic cells could be fully reprogrammed back to an embryonic-like induced pluripotent stem cell (iPSC) state via the transient expression of the Yamanaka transcription factors (OCT4, SOX2, KLF4, c-MYC) revolutionized regenerative medicine [cite: 38, 39, 40]. Transient, cyclical application of these factors *in vivo*—known as partial cellular reprogramming—has demonstrated the capacity to erase epigenetic aging marks, restore youth-associated DNA methylation profiles, and rescue tissue regeneration without forming lethal teratomas [cite: 38, 40, 41].

However, delivering viral vectors encoding transcription factors carries immense clinical risks regarding oncogenesis and the loss of essential somatic cell identity [cite: 40, 42]. Consequently, the field has aggressively pursued "chemical reprogramming," utilizing small molecule cocktails to manipulate core signaling pathways to achieve rejuvenation without genetic alteration [cite: 43, 44].

Inhibitors of the TGF-β pathway are absolute requirements in nearly all chemical reprogramming cocktails [cite: 43, 44, 45]. High-throughput chemical screening identified RepSox (also designated as E-616452 or ALK5 Inhibitor II), a highly selective ATP-competitive inhibitor of TGFBR1/ALK5 [cite: 46, 47]. The application of RepSox alone is sufficient to entirely replace the requirement for the SOX2 transcription factor during the reprogramming process [cite: 46, 48]. Mechanistically, by profoundly blocking the TGF-β/SMAD signaling cascade, RepSox downregulates mesenchymal and differentiation-associated genes (like Snail), preventing the cell from becoming trapped in a stable intermediate state and facilitating a mesenchymal-to-epithelial transition (MET) that is required for the endogenous reactivation of pluripotency genes like NANOG [cite: 43, 46, 49].

Other potent small molecule ALK5 inhibitors, including SB431542 and A-83-01, are routinely combined with inhibitors of GSK3β (e.g., CHIR99021), MEK (e.g., PD0325901), and epigenetic modulators like valproic acid (VPA) to directly transdifferentiate aged fibroblasts into functional neural progenitor cells (CiNPCs) or to erase senescence markers while bypassing the pluripotent stage entirely [cite: 43, 44, 45, 47]. This strategy demonstrates that blocking the TGF-β signal is an essential prerequisite for unlocking epigenetic plasticity.

### Systemic Lifespan Extension and Targeting Sarcopenia

Preclinical models indicate that systemic attenuation of TGF-β can yield dramatic benefits regarding healthspan and maximum lifespan. A recent landmark study investigated a dual-pronged intervention in physiologically aged, frail mice (25 months old, equivalent to 75-year-old humans). Researchers administered an ALK5 inhibitor (A5i) to blunt the pro-fibrotic TGF-β pathway, combined with oxytocin to counteract the age-related decline in systemic ERK signaling [cite: 50]. The acute application of this A5i/oxytocin combination rapidly normalized the systemic metabolic proteome. Long-term administration resulted in an unprecedented 73% extension of the remaining lifespan in frail male mice, accompanied by profound improvements in physical endurance, skeletal muscle strength, and spatial memory [cite: 50]. 

Furthermore, targeted molecular therapies are rapidly advancing into clinical application for severe age-related morbidities, particularly sarcopenia and chronic frailty [cite: 51, 52]. 
*   **MYMD-1 (Isomyosamine):** Currently advancing toward Phase 3 clinical trials, MYMD-1 is an orally bioavailable, next-generation inhibitor of TNF-alpha, a potent upstream inflammatory cytokine that heavily cross-talks with the TGF-β and NF-κB pathways to drive muscle wasting [cite: 53, 54]. In Phase 2 trials, MYMD-1 demonstrated statistically significant efficacy in reducing systemic inflammation and halting the progression of sarcopenia in elderly adults, positioning it as a potential first-in-class FDA-approved therapeutic for aging frailty [cite: 53, 54, 55].
*   **Myostatin and GDF Inhibitors:** Monoclonal antibodies targeting myostatin and GDF11 (such as bimagrumab and trevogrumab) continue to undergo extensive clinical evaluation for their ability to release the molecular brakes on muscle mass synthesis, showing promise in reversing debilitating muscle loss [cite: 56].
*   **Lysosomal and Cellular Therapeutics:** Emerging research indicates that targeting lysosomal dysfunction utilizing specific vacuolar ATPase inhibitors can correct lysosomal hyperactivation in aged blood-forming stem cells. This intervention lowers the activation of the cGAS-STING immune pathway, thereby reducing local inflammatory signals and rescuing the stem cells from the TGF-β-mediated deep quiescence, effectively restoring youthful hematopoiesis [cite: 57]. Additionally, Phase II trials are currently evaluating the efficacy of allogeneic mesenchymal stem cell (MSC) infusions (e.g., Lomecel-B) to modulate the systemic inflammatory environment and reverse physical frailty in older patients [cite: 58, 59].

In conclusion, the transforming growth factor-beta pathway illustrates a profound example of antagonistic pleiotropy: a signaling network indispensable for the intricate orchestration of embryonic development that ultimately becomes the primary architectural mechanism of systemic aging. By trapping stem cells in deep quiescence, driving cellular senescence, and executing widespread fibrogenesis, hyperactive TGF-β signaling fundamentally limits human healthspan. The ongoing refinement of specific receptor kinase inhibitors, local delivery systems, and chemical reprogramming modalities offers a tangible therapeutic horizon for rescuing stem cell function and treating the fundamental biology of aging.

## Sources
1. [Leibniz Institute on Aging](https://www.leibniz-fli.de/research/research-groups)
2. [Frontiers in Genetics](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1220068/full)
3. [PubMed: TGF-β pathways in aging](https://pubmed.ncbi.nlm.nih.gov/37732316/)
4. [Bio-Techne: TGF-beta Superfamily](https://www.bio-techne.com/reagents/proteins/growth-factors/tgf-beta-superfamily)
5. [NCBI Gene: GDF11](https://www.ncbi.nlm.nih.gov/gene/10220)
6. [PubMed Central: GDF11 biology](https://pmc.ncbi.nlm.nih.gov/articles/PMC10793994/)
7. [Aging (Albany NY): GDF11](https://www.aging-us.com/article/202881/text)
8. [Creative Diagnostics: TGF-beta Superfamily](https://www.creative-diagnostics.com/tgf-b-superfamily.htm)
9. [ResearchGate: Rejuvenation by inhibiting TGF-b1/pSmad](https://www.researchgate.net/publication/280255159_Rejuvenation_by_inhibiting_TGF-b1pSmad_signaling)
10. [Aging and Disease: Tissue Fibrosis](https://www.aginganddisease.org/EN/10.14336/AD.2023.0222)
11. [MDPI: TGF-β Signaling in Senescence](https://www.mdpi.com/1422-0067/20/20/5002)
12. [PubMed Central: Fibrosis and Aging](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529747/)
13. [PubMed Central: Cellular Reprogramming](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861195/)
14. [TNF Pharma: Pipeline](https://tnfpharma.com/pipeline)
15. [PubMed: Therapeutics for Sarcopenia](https://pubmed.ncbi.nlm.nih.gov/40165996/)
16. [GlobeNewswire: Sarcopenia Clinical Trials](https://www.globenewswire.com/news-release/2025/04/24/3067801/0/en/sarcopenia-clinical-trial-pipeline-appears-robust-with-18-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight.html)
17. [BioSpace: GLP-1 Sarcopenia Trial](https://www.biospace.com/press-releases/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-in-sarcopenia-frailty-induced-by-glp-1-weight-loss-drugs)
18. [Dovepress: Sarcopenia Therapeutics](https://www.dovepress.com/article/download/101558)
19. [PubMed: Gerodermia osteodysplastica](https://pubmed.ncbi.nlm.nih.gov/39234801/)
20. [Frontiers in Aging: Stem cell trials](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2023.1148926/full)
21. [ARVO Journals: Crosstalk Wnt Notch](https://iovs.arvojournals.org/article.aspx?articleid=2266597)
22. [PubMed Central: Notch and TGF-b](https://pmc.ncbi.nlm.nih.gov/articles/PMC2173673/)
23. [MDPI: Fibrosis Signaling Interplay](https://www.mdpi.com/1422-0067/25/19/10803)
24. [Lund University: Crosstalk Notch](https://portal.research.lu.se/files/101078168/Cross_talk_between_the_Notch_.pdf)
25. [PubMed Central: Wnt/TGF-b in Senescence](https://pmc.ncbi.nlm.nih.gov/articles/PMC12868629/)
26. [PubMed: Mechanotransduction aging](https://pubmed.ncbi.nlm.nih.gov/40488107/)
27. [PubMed Central: Rejuvenation approaches](https://pmc.ncbi.nlm.nih.gov/articles/PMC10015098/)
28. [Frontiers in Cell & Developmental Biology: Reprogramming](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1546423/full)
29. [bioRxiv: SB000 Rejuvenation](https://www.biorxiv.org/content/10.1101/2025.06.05.657370v1.full)
30. [Fight Aging: Epigenetic reprogramming](https://www.fightaging.org/archives/2025/10/a-review-of-the-present-state-of-epigenetic-reprogramming-to-treat-aging/)
31. [PubMed: Gerodermia osteodysplastica mechanism](https://pubmed.ncbi.nlm.nih.gov/39234801/)
32. [PubMed: T-cell Immunosenescence](https://pubmed.ncbi.nlm.nih.gov/41398262/)
33. [Fight Aging: Frail mice Oxytocin+A5i](https://www.fightaging.org/archives/2025/09/life-extension-in-aged-frail-mice-via-reduced-tgf-%CE%B2-and-increased-oxytocin/)
34. [PubMed Central: Osteoarthritis and ALK1/5](https://pmc.ncbi.nlm.nih.gov/articles/PMC6363221/)
35. [Time in Cologne DE](https://www.google.com/search?q=time+in+Cologne,+DE)
36. [Aging and Disease: Aging research](https://www.aginganddisease.org/EN/10.14336/AD.2023.0222)
37. [LIV Hospital: Anti-Aging Research](https://int.livhospital.com/anti-aging-research-2024-new-for-2025/)
38. [PubMed Central: TGF-b fibrosis mechanism](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529747/)
39. [Korea University: Collagen and TGF-b](https://pure.korea.ac.kr/en/publications/enhancement-of-skin-longevity-through-tgf-%CE%B2smad-signaling-pathway/)
40. [PubMed Central: Osteoarthritis](https://pmc.ncbi.nlm.nih.gov/articles/PMC4249809/)
41. [Regen Health Solutions: Stem Cell Quiescence](http://www.regenhealthsolutions.info/wp-content/uploads/2019/06/Quiescence-Good-and-Bad-of-Stem-Cell-Aging.pdf)
42. [PubMed Central: ALK5/Smad signaling](https://pmc.ncbi.nlm.nih.gov/articles/PMC6494915/)
43. [NSFC: Stem cell aging mechanisms](https://www.nsfc.gov.cn/csc/20345/20350/pdf/2016/Current%20understanding%20of%20the%20mechanisms%20of%20stem%20cell%20aging.pdf)
44. [PubMed Central: ALK5 inhibitor induction](https://pmc.ncbi.nlm.nih.gov/articles/PMC8536445/)
45. [HuaSan: Hallmarks of stem cell aging](https://www.huasan.net/wp-content/uploads/2025/09/Hallmarks-of-stem-cell-aging.pdf)
46. [Aging (Albany NY): Tissue levels of GDF11](https://www.aging-us.com/article/202881/text)
47. [AHA Journals: GDF11/Myostatin review](https://www.ahajournals.org/doi/10.1161/circresaha.116.308391)
48. [NCBI Gene: GDF11 database](https://www.ncbi.nlm.nih.gov/gene/10220)
49. [Aging-US: GDF11 circulating concentrations](https://www.aging-us.com/article/101865/text)
50. [PubMed Central: GDF11 controversy review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10793994/)
51. [PubMed Central: Crosstalk mTOR Notch](https://pmc.ncbi.nlm.nih.gov/articles/PMC2173673/)
52. [PubMed Central: Fibrosis and Senescence](https://pmc.ncbi.nlm.nih.gov/articles/PMC10529747/)
53. [Aging and Disease: Aging review](https://www.aginganddisease.org/EN/10.14336/AD.2023.0222)
54. [Frontiers in Aging: ECM and Longevity](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2022.935220/full)
55. [Stem Cell Conference: Westlake](https://stemcell-conference.westlake.edu.cn/)
56. [PubMed Central: Small molecules reprogramming](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798543/)
57. [MDPI: Small molecule cocktails](https://www.mdpi.com/2073-4409/13/23/1931)
58. [PubMed Central: RepSox Sox2 replacement](https://pmc.ncbi.nlm.nih.gov/articles/PMC3335195/)
59. [ResearchGate: Six small molecules reprogramming](https://www.researchgate.net/figure/Six-Small-Molecules-Used-for-Reprogramming_tbl2_301758608)
60. [Harvard DASH: Small molecule inhibitor RepSox](https://dash.harvard.edu/entities/publication/73120378-f655-6bd4-e053-0100007fdf3b)
61. [PubMed Central: GDF11 controversy analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC10793994/)
62. [PubMed: GDF11 and aging biology](https://pubmed.ncbi.nlm.nih.gov/38235060/)
63. [Frontiers in Aging: GDF11 meta-analysis](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1736069/full)
64. [bioRxiv: GDF11 and IPF senescence](https://www.biorxiv.org/content/10.1101/2024.09.06.611670v1.full-text)
65. [Frontiers in Immunology: GDF11 review](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1323670/full)
66. [StemCells.la: Anti-aging treatment](https://stemcells.la/stem-cells-for-anti-aging-treatment-in-2024/)
67. [NB Science: Advances in Longevity](https://nbscience.com/advances-in-anti-aging-and-longevity-stem-cell-therapy-in-2024/)
68. [PubMed Central: TGF-b localized delivery](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602941/)
69. [Fight Aging: Frail mice life extension](https://www.fightaging.org/archives/2025/09/life-extension-in-aged-frail-mice-via-reduced-tgf-%CE%B2-and-increased-oxytocin/)
70. [Mount Sinai: Lysosomal dysfunction](https://www.mountsinai.org/about/newsroom/2025/mount-sinai-scientists-reverse-aging-in-blood-stem-cells-by-targeting-lysosomal-dysfunction)
71. [PubMed Central: Crosstalk with Notch/mTOR](https://pmc.ncbi.nlm.nih.gov/articles/PMC5204325/)
72. [Frontiers in Oncology: TGF-b fibrosis](https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1649179/full)
73. [PubMed Central: Notch and TGF-b review](https://pmc.ncbi.nlm.nih.gov/articles/PMC2173673/)
74. [Selleckchem: TGF-beta inhibitors](https://www.selleckchem.com/TGF-beta.html)
75. [PubMed: Immunosenescence mechanisms](https://pubmed.ncbi.nlm.nih.gov/41398262/)
76. [PubMed Central: ALK1/ALK5 modeling](https://pmc.ncbi.nlm.nih.gov/articles/PMC6363221/)
77. [Max Planck Institute for Biology of Ageing: Publications](https://www.age.mpg.de/deelen/publications)
78. [MDPI: Senescence and TGF-b](https://www.mdpi.com/1422-0067/20/20/5002)
79. [Max Planck Neuroscience: News and research](https://maxplanckneuroscience.org/institute/max-planck-institute-for-biology-of-ageing/)
80. [PubMed Central: Delivery systems for neurodegeneration](https://pmc.ncbi.nlm.nih.gov/articles/PMC11849935/)
81. [MDPI: Sarcopenia delivery systems](https://www.mdpi.com/1422-0067/25/19/10766)
82. [LIV Hospital: Delivery systems in aging](https://int.livhospital.com/anti-aging-research-2024-new-for-2025/)
83. [ResearchGate: Sarcopenia delivery overviews](https://www.researchgate.net/publication/384712214_Advancements_in_Drug_Delivery_Systems_for_the_Treatment_of_Sarcopenia_An_Updated_Overview)
84. [GlobalRPH: Sarcopenia treatment crisis](https://globalrph.com/2025/12/hidden-crisis-why-sarcopenia-treatment-matters-more-than-you-think-in-2025/)
85. [AHA Journals: GDF11/GDF8 comparison](https://www.ahajournals.org/doi/10.1161/circresaha.116.308391)
86. [OAE Publish: GDF11 aging phenotypes](https://www.oaepublish.com/articles/jca.2023.23)
87. [PubMed Central: GDF11 and GDF8 structural properties](https://pmc.ncbi.nlm.nih.gov/articles/PMC9834663/)
88. [bioRxiv: GDF11/GDF8 phenotypes](https://www.biorxiv.org/content/10.1101/2022.05.09.491247v1.full-text)
89. [Aging-US: GDF11 aging phenotypes table data](https://www.aging-us.com/article/202881/text)
90. [Frontiers in Cell & Developmental Biology: Niche aging](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1162136/full)
91. [STEMCELL: Vascular-derived TGF-b](https://www.stemcell.com/vascular-derived-tgf-beta-increases-in-the-stem-cell-niche-and-perturbs-neurogenesis-during-aging-and-following-irradiation-in-the-adult-mouse-brain.html)
92. [PubMed Central: Neural stem cell quiescence](https://pmc.ncbi.nlm.nih.gov/articles/PMC4124027/)
93. [iPSCell: Stem cell predictions](https://ipscell.com/2024/01/20-stem-cell-regenerative-medicine-predictions-for-2024/)
94. [NIH Reporter: C. elegans niche aging](https://reporter.nih.gov/project-details/10830255)

**Sources:**
1. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHi0WDeJWyQdl-rPO5l1NayP_6bxUnlXCxP1Vx-OHDu90BK_T01dJxAC94FKCiKQJu3OMMsC7CpAdiHb1XWrTuDUhK32CCUu_31LibSHLl76Vl-oLXPFLqpmIgHrVPHxnflk8fKwatjAoOl6uP-RJb_yx-Yo09jrt1jSICE-KC8ml-pujTGCcqwESBWHg==)
2. [bio-techne.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGu3fZFEt-R3eXN1EXuz-5Nr9AefRhGZlStZMMutBAZ0LUPV4sKGNjANYG1t_y66gdSaWLxpYKjenEd55gQ27QeR8IgmktfZbuXKoEUGKu_TdYqVugEIFOl8p_362DYpFF3Pi2YRnAg1eF5idl5UyCI2zUTQVnx_AN7rAc9BS59iLHa1Zn7FQ==)
3. [creative-diagnostics.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGU8h3xz8rTM-1gSp7svJCTszzpYCVxFij8_C_W2sdniTvaaxtB6FXjqoeNf-b5J9Sk4a8gkFhYgeX5e24h3NArxA4SXNbGrDvhtQafKAZ-1hz_FD0r1rMM9-jSRbkcsJbHwcQC_UMdOs86zuTmOYat)
4. [ahajournals.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEycsmCuNYMOGbtS0fqOI9KKs8yeXuhn9edp21c8qAMuVcxMnTDIehoR5rQFfjzyBypj_CuzHo5VEQoEK8CBrxbwVo_6no8FiAkI61lAxqO39RqGFax7SYjBx02u4NmNvMD2qreVrPzEb2Wv8dO1LvJTPgj)
5. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeKpEotCO4ZlKF3mvlsvXbDrAgP03uSWbUN7XjAwBjoPZpn6MXrpYZeY5EEFYTaiucPj4zRcRM-Qh1I9wJ5-wc8hQAtNMsBJ1EFmCq2mqGM5NJhS-BbdRy56sA6f6RJcTQDA==)
6. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFnOUqsCj2qzhYAFlDZUiHqqzb33YCSKk755vchioqhTr-imNMyje3nODB2IdHLsHM_z3ySamv6GVpVFonvtTOtgUmOHrgtqhR341btSOvRKW4QIIKelpnPk80U7xpyTvnPMa82CqjC1A==)
7. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEO7kQ8lCfd1CafJnDh3dhoI_0VnAw1T6lpkS8V20qf-Xgm10QDruX5lfs-JMx3ALDOBOvXkOA8nq0boZhfc0IDvm2CjqI_W5II8Az7DhLKdADFGt53gtjopdO3JTN1MnHuQPcJY_S0)
8. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFp_NhxvqzCYPvbQKwen5Ut6UA2jL6yjxdLB8hFh-XeHJxop2p6hPAMOjIl2xy5prH0Uv0YJp7yeK0fkK2NREeeDo_Tp6IfSBaqH2cmnpG_bZKq3mcRgbYd7yIIANxqDhIJhCXj8tUp)
9. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGv0hGmHHG7_fjoK0zE0cb8WE2i9zzUTrVDvOaB8PG_mPzMovsn18uMYVoJGXQ81qUcgdCUtLMmgkdiFvZYXWEbqHGkzuVsOI7YEY5w1wx1DqS3CMaCV3yxsVPvt86HzrxumJE3GYnO2oVHY6ruIw9H0clbAGksZxBON_IMlAYdZCMYGxQc4c7SQWtM)
10. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEJpturfrK-UBbIwnXJLfzL4yvq1tz1zO9OS4TNFrkLjbqfbWlHgVrwKB_y6ohXkvXdVKWe9n0wX3mryCnvWY_9y71sUQT4WrM1upY8dd_LsHn9awEuDtYS84FtgIUZ9ICfs3cKaHHJ)
11. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeIZIKcVHyty5jayuuGdZ6JxmxJmuiKV9I2XwhXITkKYdYS8GgkIflzC-5d-Yv3bUNViw0a1Kq34zFQ3U8HlQlMwDhIT62SWoZ1STLJjZeu3pAYO7NFnMdjjtebjvTg_lwdQUN4n09)
12. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH51RDh_fj5jZT7nSL1xjJJTbzmXqVBOw3ScwTz2Cgi9eEqcM7wkcS8QzYmQKzYQPnn6c-3K_aDwhOpkiI0l-eFIbq_uDYqOB_nHAeJ7iOp8RI4tYC5Uk1GbW-1iZIDi8iz46PJ2ttelA==)
13. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF6nGTO_k4p1swjxjhibcjhKkcD0edBATy_TsJGmnb9ZfLEQcZjCyx8g2TZuEnCI6syO6ksAF5Dakoy4bzuU0dgG2oYPKk_zGM47KQ1v89r7T9hvhHdu0kScuWJbqCRHIhP9Wphum1t)
14. [regenhealthsolutions.info](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOQO3K668BS6EIZzeHkxiYlkgvtqfsgs8BXdIh_dY8yd2p9HFoIjLZ5RGehoX9WBZRDIbyW6aCTMSYZeesTgBUsKb_z2wvyjDDy5NPaqvukCHCc5F7a9uiESluVpUJLIQwuHXKN4IyMOE5rGwRHpyqPTOgWQ7wHdQHyjFLkpeKzninByzkuV_THi5coiHoMlunxc1kwHshnTyjKQoazMXSgCLQiw==)
15. [huasan.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuIcumusSgCmuDOh6s7cSvuZxa2qVQY98pc6jSn2B4efG4ArsWAV8rEV2-iP7RbVs1HS0a-0kGp0nCqV9EX2Pxrx6r5_-uQ08oaXBrTy-1CqspDofZXDP611gPNZ8LV1kN229R9f_wrPlMeArY32_XCHRZfByxMqn7Lsns6CKp9vyOFhppbFBg)
16. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGShXGa0MLJjCqzsLpWPB8t9N84VY4_QXgGyRL8PuQU4cGTYABsjBjmwNcdwbhCt4J_daUxfbnhmLD9IIeBkJhPBeDna74Gnc2lsHzwKefJcNq8PLU5abeBksXGxsmQAqhvveTesLQ4bxwOiXyS1Ar25frUtZKbSGNrhymG7SOSXMihhty1AAppNH4Un4ndnz4z2MAMkHnnb52VPELNYhMmksc=)
17. [nsfc.gov.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIn_MpsNeeo2cFCCHPTzNYFZnN1_Jy252cMU5MlzQYfwSUCUJ-WTkhrngvWiecYEh8TFzt85_KevB_nt0YUTMDVYEQEZPQYxJeUOju6wmy129zvS10FzHvDbdHf8o_66JpAJRkEed4JROqA9b3PTRzf7X5J75dwwE2Z8X4irLGR-H-2tqbY-6iKZexBRKgujLUSWGacdF_nrDfPltUrpR1jWkm8Eec2kiBZqDBtOulxdVpYkkN)
18. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHPakEVxhxJjHM3nMhU_O9WzSoX6fKckThxDleh6mOnnNOPWRpQl_2SxI_so3bnT9gbWSBfTBShTP9Twwlvb6WCAVtOt4PWMUl6vYpRfhIKuv1FyTeMsvQrd_uXkMY36g==)
19. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGa8jEBW5cOxA1rWuLOiKij9xzzQ3PnqHEGAmH6IwjMPVgvhCQBQVoe3kXUi2ribFfpYzWkFdwc9S0dNolvmGit-cbaUiJZEWdwiLBQcfG544UsJ5UWtr0FPnbAMaaTE-4ORDoUJk6DXQpLCdlcENII9_9OIJEDldbXrVd5zTsc0bNYWzthGYMljqdzWdDzPFkHL2MzPHRi_Z4=)
20. [stemcell.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbDxfpcj73Q_-LMCINfetUpwUWKKgUol7vyHTw-p5nCqnDX-AGMDmuX5RC5IVt5MHLorXG1fJc2uMpHEzwdK097__Zy1UL6rygPIuhLast_5FmUaMR2LJEvqk-bEc7dhN9kiOuIXBmJENeIkxUu82Ycm0PlhpNY-jvXqNiAgC7wl9kl51Zq6MIyx2WFKozehbfkf2ek6ifoBGJK6ytucWsPkDQBnyEgyChpfiwWmFQAhXjYLnNXNSV8vKfYcJJl4i9FnbPHN0FigkXMRXUpqvzwCuxUgbpVn5AOR8Lo0r_VQehlvRVVhBrjg==)
21. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTAeV20fQ8ccuKU7qWsZYzz8F9LluQZSxMsc3KnIvoD36BnX1wZ3xAZGQhzaol5lQC8lxEUJrziHIcZ30_mZIGlsVCMN5PaDmDUEsJTTOuCjOkrsoaCWifgSuu-qGA9uYlL4zyWr91)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHsGVY799VI9n6VFqKTKWa9t3un3Kgd3Lyx2z1iXEubM8j17Reyo8f2DL6aUouFAby63Wi6Rf0MzXfRwsMZLNMdNcZEVyIZCZHhwFZnpbvjaq_7wNKgfPv3x0M1IcyBi9u52grDAPiR)
23. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0RTAL9M3m5XKMvPDCQLMbkEKMzcHeIVG9a60E5CRV9-zs2a7aYG-SqqrYjEeLXKLGJPVBooAJxX8gm46FEYU6w9_Dh_e8tmnCj99WLz0MZLTZcXyYwGOorBgfxC0uJg==)
24. [arvojournals.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEd84mZ74vu613fxw1RjIE69qDdUtKxgzLtjeGGa8D0T0o4qY2nf6GCBwF0mLt7m8RB7qsO6LT17AgQa_wP5S3keE92UHqS2QE30U0_n6spxR3EEOeq3bmKDbML2LrWmYZ5XKUAEn8JxQkTvzAVp1eCrO0=)
25. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEvgwQyltONaMugqRan8E3RIOLhKWmmAxu4B03wAotoH3cgODj_tDd5vua7PVAcIPiNLsC27zMuzboG6tGTBNFGxoJ_3Z9aWH883oZaTmTCSvnsetb5WWWraMnaMQo7JEA=)
26. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4a3Ml9maPkrq7pL9Aq7ots7otpK1h5nkDKqOxfazEb-OlzPuQDG6sgk7M4vKIKiUsYdKyKfSIIDiinuRCaSyydQZYBHRJ5DucQfvzEPl0hFoLW91IGrPcgFgOtPL9gjPjnHdpxoZPfX7tku4NIK9MdKWUCnHPX7PODE7CG8OnC8iCN-1ZVh6n)
27. [aginganddisease.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTcXYKTLcSHwVW1c3eUpHqZ6JZZtEsWH-kNsdNxHXYFbQVj_uq6uhE5G4kQFoaScd7083aj65zkLyOxp7HSMRDoOXj-T9kZyGH4XarnUrcni4X9myd8Y4rUPzBNIKM3YIHRwOqi2uZx9llqouFFQ==)
28. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHI2ACKEukOUyxcmAOJYqjC6HYlhyWQ34KOwgAV4_jyC8aCzrWBLsF5MsTyk5F9W-cM-E4gEU21g8IKWt8WVxhlfzI8Dfn8t_Srh-94wUxmB05olvFK88bG_Qmboe7B9lxC-RXcgjk2gw==)
29. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH7JZaFxhJQcGfN52waHq9ECDs8Vf9rahuVJEzgoizdih2dcRt4Czsy6qWockKienw9wX5fgsIzRXg1gPDfVlWIsOCPUHnV9RAPUwnz1hIFd_nrlWSzygwi3dUqAVqLLw==)
30. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGCaXqH1R67E8AsvILQl8L3G80czwEHb5ehUJtWjfRbrF_kStEH5YSJxTbVeReJ8OjL7tE1JMHKyGeDiOaNw7XZVUjcU7qneU3kVf5FOWuLr7K5iLbhZxdWH-GLNWmQZy0LLMwN8IW9)
31. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEa4U2Ouh8t9QrBQSsFGMsuB96UKmVjW46O34lLeINw6Bes7zKhZrKzD4sGUPy8nR8F3joj7z3rpON2tT3NFMRMLZFcRQGcjL3aTTWMqoiSZeZXTmvs4Lv53TzEUpAtWQu6UbrvTeUSw0ifrFga5-x9yTmnRzMVw43SRxU=)
32. [oaepublish.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwiK2nWfZnyfvjCRQRvbOlii_WGUnrm2sDH0Ib2rZVs4Sdu2aVnTc5kOfyPkRjZpA-fh-UvWL9tvDtiDvRE78ZFu7bkP2bAaQdFkZf_y8PAAq-Qy-ZnrbIIy7oObAHL00E4VlfSQ==)
33. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQETmwtyrZZsCCtB4-144xDqLjeRMTAJBCYhSrU9GbOOZml_0AYkkmDg8pWghuuKXRx3RxdfFbN-vIAmBsmA0uwTz3C7OeWAo7p1svq2L8jcpq6yCBFKnoW9WMHZ-UAymmwneHYXE51CNhoWdhb8Hp4kliD6meq5U-rHdjqSXjBki5rZJtD_ST4yTg==)
34. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVLLjUtYvhB766hhACTRCuYBBnsASwwkj_nkxNztDshKJ4a_DK1TlP1SUZggA-S5zjAiHS_sO5WwQVBxd05CSOCgX5K8obDmVSSHXaWzmq8P_RB1c9TQLl-kc1UgTR8Khqvgo5kQpLQPeqgRCi9WxU1PoRMhRb2RQ2DdBCfO65wuA49Spaw4hlpdVaxu74)
35. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFjq3SynhxhAZ6Ap2tzxW51oF7XRl_CWLBKYFew8zgN25C3Owkda2ep_3PjUOxkYDbBKq5NVC-kLIlwysg5YxEeesS6-Scuk6JFt4cdDrxvfi8eO792hfAQjkXvV-oN5U9tPx5KgugKgzLnC7khF41RKBWhAR3InOoT5u4=)
36. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHsKRJRNXv5Nk9ACQQFCPEQlpRHlV5UrJqToP8pUEe64gIIgkYL_EtTT8MjjRTQdmFY-Zb-QIzD7rFvohLbzD6Dc5N6E_yBCPLEmPmXlhKVudZS092NuXORPZLTCk2yBnnOFw==)
37. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGgcVFYATjEBER5Xwnxlrob6iMM_YqIqEtXTjr5u2JTvdqQkj9UEdFy1_RS3yuXkoKG7RbExNKkBnr_DeuNuVDuct1V6eGb10EZMBmOew-UaJ5oQyeKwgcKI5XvIOk=)
38. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGViZEvZe_dO5atZEO2L1OsfBIjwqORZ8riIVgBBijrhUzWMLVi0CWersw9XuXAe0mu-T7yFHFxzAHwwyv98H4FACj9G-E9QPiWkTAc8Y_P-gtuOZLscAu74VlIYJ9Ogm5gV6qMc_P-BA==)
39. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQETXaSypvSGVyMSTi6pXarm4RVUHk6GGp_9Nre7HIlYvE130tuYR2tM-I1QFnT5W1N5-qfZqYP6XwNkneXJ72ZYjCOJ5ubOYBrPOPJZ12aCOubZ4IpZacQBX7Ag_hrFHVAprtKKvd5Mzw==)
40. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHWK_DWX1ARGkN4mYX96L6ItOGRL2moikWnXzacK1JFkBAx0vZgwu3iVm9c2YsuMFsS0FsySQh2-U01oQbbEbQFlHkFL2gyEbq448pgQuhYLuql07sRJp_kaN5NdanOr40wdvtCq425VXR1m2uqEzfcy_qf4D61tGXpBX5-rLSHtB7ejyCsuH57MWS0gKK1Q0K5qXS1smdfDeEm0mp1K7WkFKk=)
41. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0br7xc-8cd96pA2MkLQpvQCLulGQda7lIteGxFPGtksd7DPPr4veaxY1RsD7uaKJrXHRB-rIpefB91xDt4dSMRy3eoK6htgfzb55zlTIw0g2eNCf-Exy9AnsoXqk5SO-16WkEDl-GFxw_w5jcuvDnEhBLoXYIemt5lNvoVNadLy7VKyE836PtNTHYs0W9Aik3c0XshCexFg7g3w00byxMZF_in2St_T_fb0k=)
42. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQElzIIwnPQXZTUkUlrB0XtCXJKshlP-KMGLsBoahV3TWw7Oo1XrgvTwLTqlOJ6eiuNg0uERf3HBs-aDPxtX5_NVg0SDaeFkh93_sJWuvvAD4AYyOucREtpdEV2l4yMx9eUMNxgI9wsJxVSpOyNvn6qNYycrJubH)
43. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHpJ85Y0aClgnrQ1E5gP5soRi3qOjCBZgCddjj7rgBXgrQWgGWUe5miXYz09WZhuEwpyx_yxUg730OlrtViT2FuXusAE84-xE9ArPBDJxpE6QTPNOGpfO6_McJ63JGN7IBd-82j66Zs2w==)
44. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEAr-7eJ8Nklm_cCRBagSSDjpAvqqrASMGZALvkPRnKVYIFjPV2y0JOJLiIYKoP1KWB9RH1v3QpDZsK05dghRV0ZQBzJm4KttPHeDmI_K-50t_hrhem7ml1dN5kc6lOhg==)
45. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIq1Q5EqTFJvPqOZvQX2G44Yi8fi20KrQvi8_lOvIZAqF8LrVzCVXJKN7Za8wMopWfRbNiQdukXVHDt7fMZmzWc3eVyadQBYpo4WXr4AwAMV5tv-BVrUgf0hmDBETLGbd47KMyfylOMh86y5ua_LmDCqa5ggphDyAuEBQpdNRjhLOVEI0crfzBoMNLhsRxChp9Hlo=)
46. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEsfqFbTHgQO0lt3v43C2WH_Edlu8GoOynIHZj2X0WR4CnEQsRg6cVoGygQEoG58DCPwGcrCTYO88gOEtRuG-Be8tIqkkv1XxZS2Wa7OxySucebuo26vNiH7d7GlE3KL8tm05bMat0U)
47. [selleckchem.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE5cmFzWGBTZk9FDMixukXJKAgcHh4SoxsWVQe0Fgsh5sFfOKjWYJK8Ju1MMqpsJJ996Xuer-lVYj9b1IUt29Gjx2y2PERP9I87Od7rAm2s5-01qPeOu4isVEioJRFt8g==)
48. [harvard.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkSuzsAPrWI0KMngDCHPgvHNfbuR2gv2mIWsXIOuWyXOtgbdZKzaYLdImQAdMd8QpovT6olWBtF8pGXOllBvZJy1GCCYnAfNh54VJ3DlLNh7EqCOdwQ7Y5Jrr4iaN_6cX8ih9BJSjaYlHvl0g8VtYlMa6GEG9BJe_Vu272TqNWqwmSpUXJnjLj)
49. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhCJQYquJgCA1OMcA475AJIA5uzuAt2YDDOXW8bFrx1MP_Uc1-uofTLADiFOJfA2ArTbPWAYd42eyq6QLKTgdcUu0VQzLtu7Cx7Mr5IIn-fzMkQUtFEe4sRnWS76caI48QJLjlrCFCVw==)
50. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG5rd6awuPDasIlRRHR7Y0cc4TczZZ7fWmgJxjUKXrjKLNENl4JrZxT8ktZvn__qF6bJcsSPAs_9ICc4mcOR_5nH0mN98LZ646i1pnmDIV0LqlQQuc7eFv6eWPjHWuxmZ1xmUpdAnNwKw53S5jMYusHfw_Hwam4rNEYNZBQhLuRTpcgyMGBG_hp7iXza8NaCE5PhUfeS1-CSwy_EwQ4ODwJu9BIhpuawdlZWpXCNcWxnIMg)
51. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0wU4Yi6S6JQ4n3oze9CcUhNUvs3d40s4vtP662eqGCYMcUTUhvFqdbzC8UbJVqP-UlMCPjQFWFIeeY1QnmDR_ZzgAhLr8PkfBDXoZymaq1Ra3hWYk6yJM_ogXIn2yQQ==)
52. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFFN4upgbLi9omjK_3M6Yw8zrMM4pHb5NsAj2iIgxAMVd-cW74QPlgtMF5uo0V3qz3P1hO5Bzf4AobGfh-iSbdQVwjyk7OWT6L6EaEdq9BPKxG90NvmH2evYhX2-HeI-Nc=)
53. [tnfpharma.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF70Z9eSZzdvRgpSVOj4mk3iOzjs-eydp2DV474SXFbZYbee03ez81ILHy9H0KwJI4IutGphSSKD8rvQUlfdQw2puFCp6OYXMU5aRry5T_sEJTDfiI=)
54. [globenewswire.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTNmbU2tCj11aS8lHwn2rvrfNIakVpMQuBZhcPwiLEGTqLx5HEqQyptV5qE29VHE5-HzAirIZcYoeQAD3xyt8_3qR5X7v2MVcy4_YVqCtutKuryCz6gcjAknHNONREj4fQO5m6TQaYdvT_6JQ-jIzK2l46DCdRX8J8qdCmByeUSKKpqdOD-Zr7ABhMktxtQ_dyqKcknaBanQ0C4qG6nSs0Q_Ia3JZWru-6sp6J58JCzU39Ydts0TTUwR_6opMS-NwZRijrJMl8go684tnSxk7TQ2mRZC__WteFmdAFxux2O-HqLjjgkNO2h6vH1_fOo9_WmC6c7S90RsjU3TopFcSm7swJI8Rp5w==)
55. [biospace.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF0-wL5AHhpwuzQOyZSRq_URz6X3doAV-n0WmVluGCQodb4a6LIF-TKvdf6wgWIEhrOnx5JZ9EO8PzO1hFK_G4hHjCRHRkftKVEfS5JtXaKbdKe6PDmrFIXRs1Kxj26lIkt-_4CotuxCmB-neTnfu7801WJMYon1neMM_mT4YitdF9IPdoa1WBr-OuFkV4BFQAD1HSYgaz6PzyfBopk5dXHpr-Je7q0HsrIQFsKQNynBI4Pc7w63L9NnZ4QYOFxXUyYXLfglQhfcWRnysbsd0jZhhujT3Bc45GcKjDznv2tHQ==)
56. [globalrph.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFty7EeJlmRW9phRZ50540bSfEiouQ81hAF5b3aJvNz5ZIpUxq7K4NG8bNl6MuCttJR9hjWlDPHfmQOoZ-Qq60MBFUFTKIC3QhkqM4jzj8HZ_idv-0iHFmOy1W54G8N1BtQFE3U8jm0hVULYwb45dfSmH9FDitOt7Ueg3C3dI4qSJVcyii2M6_ne2lCNSj1LQMfWIScFzSaiV_OMc60t_w=)
57. [mountsinai.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7gHnaPi1jkBL7V8wZaQYmGcc09p2eu1hKK-XILu_Obaqs8PQXNt4rRqE9oIPG2YaTskRTo7gHazGi1xArwjflmWunzh12dmBKx7jDYyLeE3NHAeCtfV-ZiJjNbONr7oF5GSQtBG4zXHcL9ZAGh10vUJ27DRtbHdZ5xeWhQZ1xT2JUnY6yIgIyKTallsoz8KwsCMYKjpfVP2QibyR8ENJobFF6Wo0dPPS698b_letdlguMwt88NOEd7ztz2dnvVisN)
58. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEIdZfoEG7BaAKbYsGFKBrEWA-z6-tSxVs8nDUjMxrDmBwD0CeEECb5JneD3EmpLQsqO0c4iA_Tnj2ON-0zKZCSJU7siOqSWdoUv_rmmmxLV71rMNtXKdhMlkuq5meABwNuUobSVvJvRHAiwmkJex-13QTwLynR8wOPoXOwXQ7z-50NqIrL3RXfzA==)
59. [nbscience.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtW2mSLKzDYpQtVbJqorZqdtsvjmgVMIDpyEKuCbZ9bhe8M8Ho8yD8f7cqL-XX-cjNw-_49WT4aZlaCW1tTtCD8V8jR5-wnlHvIwzCEtGskH1_8KKbAjfvL5-vDqhXxRsVXDGP8VxBSCNQDLcs455nWJpvOpo07LpafYjNvRcXg-Q1jeU1XLWVcl7x)